Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer

Prostate

Volumn 73, Issue 5, 2013, Pages 500-511

  Hashimoto, Kohei ^a   Masumori, Naoya ^a   Tanaka, Toshiaki ^a   Maeda, Toshihiro ^a   Kobayashi, Ko ^a   Kitamura, Hiroshi ^a   Hirata, Koichi ^a   Tsukamoto, Taiji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

anti tumor effect; neuroendocrine carcinoma; prostate cancer; somatostatin analog; zoledronic acid

Indexed keywords

MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OCTREOTIDE; PASIREOTIDE; RAS PROTEIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 2A; SOMATOSTATIN RECEPTOR 2B; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROENDOCRINE TUMOR; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATIC NEUROENDOCRINE CARCINOMA; PROTEIN EXPRESSION; PROTEIN PRENYLATION;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CARCINOMA, NEUROENDOCRINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, NEOPLASTIC; IMIDAZOLES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OCTREOTIDE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RAS PROTEINS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 84875207898     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22590     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69-90.
2. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F,. EAU guidelines on prostate cancer. Eur Urol 2008; 53 (1): 68-80.
3. Debes JD, Tindall DJ,. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351 (15): 1488-1490.
4. di Sant'Agnese PA,. Neuroendocrine differentiation in prostatic carcinoma: An update. Prostate Suppl 1998; 8: 74-79.
5. Ito T, Yamamoto S, Ohno Y, Namiki K, Aizawa T, Akiyama A, Tachibana M,. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence. Oncol Rep 2001; 8 (6): 1221-1224.
6. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N,. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004; 45 (5): 586-592; discussion 592.
7. Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Tsukamoto T, Shappell SB, Matusik RJ,. A probasin-Large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 2001; 61 (5): 2239-2249.
8. Masumori N, Tsuchiya K, Tu WH, Lee C, Kasper S, Tsukamoto T, Shappell SB, Matusik RJ,. An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. J Urol 2004; 171 (1): 439-442.
9. Uchida K, Masumori N, Takahashi A, Itoh N, Tsukamoto T,. Characterization of prostatic neuroendocrine cell line established from neuroendocrine carcinoma of transgenic mouse allograft model. Prostate 2005; 62 (1): 40-48.
10. Uchida K, Masumori N, Takahashi A, Itoh N, Kato K, Matusik RJ, Tsukamoto T,. Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line LNCaP. Prostate 2006; 66 (5): 536-545.
11. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B,. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94 (19): 1458-1468.
12. Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A,. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol 2007; 211 (2): 533-543.
13. Patel YC,. Somatostatin its receptor, family Front Neuroendocrinol 1999; 20 (3): 157-198.
14. Hejna M, Schmidinger M, Raderer M,. The clinical role of somatostatin analogs as antineoplastic agents: Much ado about nothing? Ann Oncol 2002; 13 (5): 653-668.
15. Reubi JC, Waser B, Schaer JC, Laissue JA,. Somatostatin receptor SSTR1-SSTR5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28 (7): 836-846.
16. Halmos G, Schally AV, Sun B, Davis R, Bostwick DG, Plonowski A,. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab 2000; 85 (7): 2564-2571.
17. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G,. SO M230 a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146 (5): 707-716.
18. Chou TC, Talalay P,. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
19. Topaly J, Zeller WJ, Fruehauf S,. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001; 15 (3): 342-347.
20. Bok RA, Small EJ,. Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer 2002; 2 (12): 918-926.
21. Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ,. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004; 64 (15): 5489-5495.
22. Weinstein MH, Partin AW, Veltri RW, Epstein JI,. Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996; 27 (7): 683-687.
23. Sciarra A, Bosman C, Monti G, Gentile V, Autran Gomez AM, Ciccariello M, Pastore A, Salvatori G, Fattore F, Di Silverio F,. Somatostatin analogs and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma. J Urol 2004; 172 (5 Pt 1): 1775-1783.
24. Pawlikowski M, Melen-Mucha G,. Perspectives of new potential therapeutic applications of somatostatin analogs. Neuro Endocrinol Lett 2003; 24 (1-2): 21-27.
25. van der Hoek J, van der Lelij AJ, Feelders RA, de Herder WW, Uitterlinden P, Poon KW, Boerlin V, Lewis I, Krahnke T, Hofland LJ, Lamberts SW,. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin Endocrinol (Oxf) 2005; 63 (2): 176-184.
26. Schmid HA,. Pasireotide (SOM230): Development, mechanism of action and potential applications. Mol Cell Endocrinol 2008; 286 (1-2): 69-74.
27. Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RG, Oppermann U,. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 2006; 103 (20): 7829-7834.
28. Hougland JL, Fierke CA,. Getting a handle on protein prenylation. Nat Chem Biol 2009; 5 (4): 197-198.
29. Nogawa M, Yuasa T, Kimura S, Kuroda J, Segawa H, Sato K, Yokota A, Koizumi M, Maekawa T,. Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol Res 2005; 15 (1): 1-9.
30. Fabbri F, Brigliadori G, Carloni S, Ulivi P, Vannini I, Tesei A, Silvestrini R, Amadori D, Zoli W,. Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med 2008; 6: 43.
31. Mani J, Vallo S, Barth K, Makarevic J, Juengel E, Bartsch G, Wiesner C, Haferkamp A, Blaheta RA,. Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro. Prostate Cancer Prostatic Dis 2012; 15 (3): 250-255.
32. Denoyelle C, Hong L, Vannier JP, Soria J, Soria C,. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 2003; 88 (10): 1631-1640.
33. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I,. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2009; 126 (2): 522-532.
34. Guenther A, Gordon S, Tiemann M, Burger R, Bakker F, Green JR, Baum W, Roelofs AJ, Rogers MJ, Gramatzki M,. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010; 126 (1): 239-246.
35. Sewing L, Steinberg F, Schmidt H, Goke R,. The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 2008; 13 (6): 782-789.
36. Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H, Rosol TJ,. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin Exp Metast 2006; 23 (1): 19-31.
37. Kubista B, Trieb K, Sevelda F, Toma C, Arrich F, Heffeter P, Elbling L, Sutterluty H, Scotlandi K, Kotz R, Micksche M, Berger W,. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 2006; 24 (6): 1145-1152.
38. Kuroda J, Kimura S, Segawa H, Kobayashi Y, Yoshikawa T, Urasaki Y, Ueda T, Enjo F, Tokuda H, Ottmann OG, Maekawa T,. The third-generation bisphosphonate zoledronate synergistically augments the anti-pH + leukemia activity of imatinib mesylate. Blood 2003; 102 (6): 2229-2235.
39. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T,. Zoledronic acid inhibits visceral metastases in the 4T1/Luc mouse breast cancer model. Clin Cancer Res 2004; 10 (13): 4559-4567.
40. Coxon JP, Oades GM, Kirby RS, Colston KW,. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004; 94 (1): 164-170.
41. Marten A, Lilienfeld-Toal M, Buchler MW, Schmidt J,. Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells. J Immunother 2007; 30 (4): 370-377.
42. Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kuroda J, Nogawa M, Yuasa T, Kiyono Y, Wada H, Maekawa T,. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005; 116 (1): 94-99.
43. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K,. Peripheral blood monocytes are responsible for gamma delta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 2009; 144 (2): 245-250.
44. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ,. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346 (9): 653-661.